indazoles has been researched along with Hypertrophy, Left Ventricular in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukunaga, K; Hachimura, E; Han, F; Hasegawa, H; Kanai, H; Lu, YM; Shirasaki, Y | 1 |
1 other study(ies) available for indazoles and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760
Topics: Animals; Atrial Natriuretic Factor; Cardiotonic Agents; Caveolin 3; Disease Models, Animal; Dose-Response Relationship, Drug; Dystrophin; Glycoproteins; Heart; Heart Failure; Hypertrophy, Left Ventricular; Indazoles; Male; Mice; Mice, Inbred Strains; Myocardium; Nitric Oxide Synthase Type III; Spectrin | 2010 |